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In normal rats, the xenobiotic K76 inhibited the C5 
and probably the C2 and C3 steps of complement and 
effectively depressed classical complement pathway 
activity, alternative complement pathway activity, 
and the C3 complement component during and well 
beyond the drug's 3-hr half-life. It was tested alone and 
with intramuscular tacrolimus (TAC) and/or intragas-
tric cyclophosphamide (CP) in rat recipients of heter-
otopic hearts from guinea pig (discordant) and ham-
ster (concordant) donors. Single prevascularization 
doses of 100 and 200 mgJkg increased the median sur-
vival time of guinea pig hearts from 0.17 hr in un-
treated controls to 1.7 hr and 10.2 hr, respectively; 
with repeated injections of the 200-mg dose every 9-12 
hr, graft survival time was increased to 18.1 hr. Pre-
treatment of guinea pig heart recipients for 10 days 
with TAC and CP, with or without peri operative spIe-
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nectomy or infusion of donor bone marrow, further 
increased median graft survival time to 24 hr. Among 
the guinea pig recipients, the majority of treated ani-
mals died with a beating heart from respiratory fail-
ure that was ascribed to anaphylatoxins. Hamster 
heart survival also was increased with mono therapy 
using 200 mg/kg b.i.d. Lv. K76 (limited by protocol to 6 
days), but only from 3 to 4 days. Survival was pro-
longed to 7 days with the addition to K76 of intra gas-
tric CP at 5 mglkg per day begun 1 day before opera-
tion (to a limit of 9 days); it was prolonged to 4.5 days 
with the addition of intramuscular TAC at 2 mgJkg per 
day beginning on the day of transplantation and con-
tinued indefinitely. In contrast to the limited efficacy 
of the single drugs, or any two drugs in combination, 
the three drugs together (K76, CP, and TAC) in the 
same dose schedules increased median graft survival 
time to 61 days. Antihamster antibodies rapidly in-
creased during the first 5 days after transplantation, 
and plateaued at an abnormal level in animals with 
long graft survival times without immediate humoral 
rejection. However, rejection could not be reliably 
prevented, and was present even in most of the xe-
nografts recovered from most of the animals dying 
(usually from infection) with a beating heart. Thus, 
although effective complement inhibition with K76 
was achieved in both guinea pig- and hamster-to-rat 
heart transplant models, the results suggest that effec-
tive interruption of the complement cascade will have 
a limited role, if any, in the induction of xenograft 
acceptance. 
682 TRANSPLANTATION Vol. 62, No.5 
K76 monocarboxylic acid is a xenobiotic purified from the 
culture of the fungus Stachybotrys complementi that inhibits 
the C5 step of the complement cascade (1) by fusion of the 
molecule with the C5 complement component (2). Reported in 
vivo effects of K76 include protection of guinea pigs and mice 
from Forssman shock (3), mitigation of experimental glomer-
ulonephritis in rats (3, 4), and amelioration of experimental 
(5) and clinical ulcerative colitis (6). In 1993, Miyagawa et al. 
(7) showed that intraperitoneally administered K76 modestly 
prolonged the survival of heterotopic guinea pig hearts after 
their transplantation to rats. With intravenous administra-
tion, a far more dramatic therapeutic effect was demon-
strated (8, 9). K76 also substantially prolonged kidney xe-
nograft survival after pig-<iog transplantation (8). 
We further document herein the remarkable ability ofK76 
to ameliorate the hyperacute rejection (HAR*) that follows 
guinea pig-rat xenotransplantation. However, this accom-
plishment, as with other complement-inactivating or -deplet-
ing procedures, has no immediate clinical application be-
cause the characteristic HAR that defines discordant 
xenograft rejection was merely delayed while recipient mor-
tality increased in proportion to the efficacy of xenograft 
protection. Consequently, we systematically added K76 to a 
double-drug cocktail of subtherapeutic doses of tacrolimus 
(TAC) and cyclophosphamide (CP) and tested different drug 
combinations and dose schedules with hamster-rat heart 
xenotransplantation. Our conclusion from the experiments 
was that agents that efficiently inhibit complement impose 
thereby inherent risks and consequently are not likely to 
have a maintenance role in cross-species transplantation, 
even between concordant species. 
MATERIALS AND METHODS 
Experimental Models and Drugs 
Animals. Inbred male Lewis rats weighing 200-250 g (Harlan 
Sprague Dawley Inc., Indianapolis, IN) were used as recipients. 
Outbred male Syrian hamsters weighing 100-150 g and outbred 
Hartley guinea pigs weighing 150-300 g (Charles River Laborato-
ries, Wilmington, MA) were used as donors. 
Transplant operations. The animals were anesthetized with me-
thoxyflurane. Heart grafts were transplanted into the abdomen of 
recipients using the technique of Ono and Lindsey (10). Rejection 
was diagnosed by the cessation of a palpable beat of the graft, 
followed by direct inspection and histopathological examination. 
Immunosuppressive drugs. K76 (donated by Otsuka Pharmaceu-
tical Co., Ltd., Tokushima, Japan) was suspended in normal saline, 
adjusted to pH 7.8 with NaOH, and administered as a bolus intra-
venous injection via the penile vein over 1-2 min. Plasma concen-
trations were measured using a high-performance liquid chromatog-
raphy method (J n TAC (Fujisawa Pharmaceutical Co., Osaka, 
Japan) was injected intramuscularly after suspension in normal 
saline. CP was prepared daily in distilled water and administered 
orally by gastric instillation. 
Experimental Design (Survival) 
Guinea pig ..... rat transplantation. Monotherapy with intravenous 
K76 was given in different doses 30 min before revascularization. 
with repeat doses 9-12 hr later in rats whose graft survival exceeded 
* Abbreviations: ACH~o, alternative complement pathway activ-
ity; APTT. activated partial thromboplastin time; CH~o, classical 
complement pathway activity; CPo cyclophosphamide; CVF. cobra 
venom fraction; HAR. hyperacute rejection; PT. prothrombin time; 
TAC. tacrolimus. 
9 hr (group 6). The results were compared with those for untreated 
controls (group 1). The best survival time with monotherapy was 
obtained with two doses of 200 mgIkg (group 6). This therapy was 
then systematically combined with other kinds of 10-day pretreat-
ment with TAC, CP, or both together in doses shown in Table 1. In 
two additional groups given the triple- or double-drug therapy, 
250X 106 unaltered guinea pig bone marrow cells were given on day 
-10 (groups 11 and 12). Finally, adjuvant splenectomy was com· 
bined with K76/l'AC/CP therapy in group 13. 
Hamster-+rat transplantation. K76 doses of 200 mglkg every 12 
hr were begun from 30 min before revascularization (in most exper-
iments) to as late as the third postoperative day (groups 8, 9, and 10) 
and stopped after day 4, 6, or 8 (Table 2). The drug was tested alone, 
with TAC at 2 mglkg per day, with CP at 2.5-10 mgIkg per day, or in 
combination with both TAC and CP (Table 2). TAC was begun on the 
day of operation, with the dose reductions on postoperative days 6, 
14, and 30 in the different groups shown in Table 2. CP was begun 1 
day before the operation and stopped on the days shown in Table 2. 
Experimental Design (Nonsurvival) 
K76 pharmacokinetic and immunologic studies were obtained in 
naive rats and with both experimental models using the therapy that 
provided the best survival time without either adjuvant bone mar-
row or splenectomy. The latter animals were killed while their xe-
nograft hearts were still beating for histopathologic studies. 
Guinea pig-+rat. Animals pretreated for 10 days with TAC and 
CP plus repeat doses of K76 (Table 1, group 8) were killed after 0.5, 
1.5,3,6,16,20, and 25 hr (n=1-3 each). 
Hamster-+rat. Animals treated with K76, TAC, and CP (Table 2, 
group 7) were killed on postoperative days 1,3,5,7,10,14, and 28 
(n=3 each). 
Immunologic and Coagulation Assays 
Antihamster antibodies. Rat serum samples were heat inacti-
vated (56°C for 30 min), serially diluted with RPM! 1640 medium, 
and studied with a complement-dependent lymphocytotoxic assay. 
Hamster lymphocyte targets were prepared from cervical lymph 
nodes and suspended at a concentration of2x106 cellslml in medium 
supplemented with 20% heat-inactivated normal hamster serum. 
One microliter of diluted serum sample and of hamster lymphocyte 
suspension were incubated for 30 min at room temperature. Five 
microliters of baby rabbit complement (1/5 dilution, Cedar Lane 
Laboratories Ltd, Hornby, Ontario, Canada) were added to each well 
and reincubated for 60 min at room temperature. After staining with 
0.4% trypan blue, the cytotoxic antibody titer was defined as the 
highest serum dilution with more than 51% of cell lysis. 
Clotting factors. Prothrombin time (PT), activated partial throm-
boplastin time (APTT), and plasma fibrogen concentrations were 
measured by standard laboratory procedures and were expressed as 
percentages of the mean value in normal Lewis rats. 
Recipient complement. Classical complement pathway activity 
(CH~o) was assayed using the method of Kabat and Mayer (12). 
Serially diluted serum (0.5 mJ) and 0.5 ml of sensitized sheep eryth-
rocytes 11XI0" celVml1 were incubated in 1.5 ml of GVB (isotonic 
Vernal·buffered saline with 0.1% gelatine) containing 0.15 mM 
CaCl2 and 1.0 mM MgCl2' for 60 min at 37°C, and analyzed by 
spectrophotometer at 412 nm. Alternative complement pathway ac· 
tivity (ACH,oJ was assayed using rabbit erythrocytes suspended in 
GVB containing 2 mM Mg· ~ and 8 mM EDTA (5X 107 celVmll. Fifty 
microliters of serum sample and 0.1 ml of rabbit erythrocytes were 
incubated for 60 min at 37°C and analyzed by spectrophotometer at 
412 nm. C3 level was measured with the single radial immunodiffu-
sion method using goat antirat C3 serum (Organon Teknika Corp., 
Durham. NC). Results were expressed as percentages of the mean 
value in normal Lewis rats. 
... 
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TABLE 1. Heterotopic heart and recipient survival after guinea pig -4 rat transplantation under different therapies 
Treatment (duration) 
Group Survival Median Mortality P P K76 TAC CP n (hr) (hr) (%) (VB. group 1) (VB. group 6) (mglkg/dose) (mg/kglday) (mg/kglday) BMISN" 
1 10 0.11,0.12, 0.13, 0.13, 0.17 0 <0.005 
0.17, 0.18, 0.18, 
0.18, 0.27, 0.27 
2 100X1 5 0.33, 0.8, 1.70, 5.5, 1.70 20 <0.005 <0.01 
5.5b 
3 200X1 10 4.66b , 6.50, 8.40, 10.15 10 <0.0005 0.16 
8.67,8.80, 11.5, 
18.70, 20.0, 24.3, 
27.05 
4 300X1 5 2.0b , 3.13b , 4.0b , 4.00 60 <0.005 0.1 
13.47,27.58 
5 400X1 3 1.50b , 5.90b , 15.3b 5.90 100 <0.005 0.07 
6 200X2c 6 10.0b , 13.5b , 16.0b , 18.09 83 <0.005 
20.17, 20.55b , 28.9b 
7 1.0 (d -10-) 10 (d -10-) 4 0.18,0.19,0.29,0.68 0.24 0 0.04 0.01 
8 200X2c 1.0 (d -10-) 7.5 (d -10-) 6 21.Sb , 23.0, 24.0, 24.00 67 <0.005 0.04 
24.0b , 25.33b , 35.5b 
9 200X2c 1.0 (d -10-) 6 3.33b , 8.58b , 9.92b , 13.21 67 <0.005 0.52 
16.5b , 23.5,31.0 
10 200X2c 10 (d -10-) 4 8.42b , 13.17,31.33, 22.25 25 <0.005 0.47 
33.57 
11 200X2c 1.0 (d -10-) 10(d-10-) BM (d-lO) 4 21.25, 23.25, 26.00b , 24.63 50 <0.005 0.08 
26.25b 
12 200X~ 1.0 (d -10-) BM (d-lO) 4 4.0b , 4.58b , 11.0, 7.79 50 <0.005 0.03 
12.08 
13 200X2c 1.0 (d -10-) 10 (d -10-) SN (d-lO) 7 11.75b , 12.38b , 24.25 57 <0.001 0.32 
23.17b , 24.25, 
26.75, 28.33, 
30.25b 
a BM, guinea pig bone marrow transfusion; SN, splenectomy. 
b Animal died with beating heart graft. 
c K76 was given 30 min before graft revascularization and every 9-12 hr after transplantation. 
Statistical Analysis 
The results of complement studies, K76 plasma level, PT, 
APTT, and fibrinogen levels were expressed as mean:: SD. 
The Mann-Whitney U test was used for statistical analysis of 
xenograft survival and P<O.OI was considered significant. 
RESULTS 
Survival 
Guinea pig~rat transplantation. Median heart survival 
time was increased lO-fold (from 0.17 to 1.7 hr) with a single 
prerevascularization dose ofK76, 60 times (to 10.15 hr) with 
one dose of 200 mg, and 106-fold (to 18.1 hrl when a repeat 
dose of the drug was given 9-12 hr after transplantation 
(Table 1, group 6), Single doses of 300 mglkg and 400 mg/kg 
were also highly protective (up to 27.6 hr). However, most of 
the rats with long xenograft survival times after treatment 
with a single high or double 200-mg/kg doses of K76 had 
respiratory arrest, which terminated 11 of the 14 experi-
ments in groups 4-6 by death while the heart was still 
beating (Table n The dose of 200 mg/kg every 9-12 hr 
(group 6) was selected as the standard for combination with 
other therapeutic modalities. 
K76 etfectiveness was ·the principal determinant of graft 
survival. no matter what therapeutic vanable- TAC, CP, the 
two drugs together. donor species bone marrow, or recipient 
splenectomy-was added (Table 1, groups 8-13). Although a 
10-day preoperative course ofTAC plus CP (group 7, Table 1) 
increased median heart survival time from 0.17 to 0.24 hr 
(P=0.04), the addition of optimal-dose K76 to this regimen 
(group 8) resulted in only a marginal prolongation of graft 
survival compared with that with K76 alone (24 hr vs. 18 hr, 
P=0.04). The results were essentially the same when the rat 
recipients were also splenectomized (P=0.32) or primed with 
guinea pig bone marrow on day -10 (P=0.08). 
None of the guinea pig xenografts were normal (see below). 
The high mortality (>50%) of dose-effective K76, whether 
used alone or with other treatment, was almost always due to 
respiratory failure. The lungs of these animals were archi-
tecturally intact, except for evidence of smooth muscle con-
traction and a characteristic neutrophil infiltration beneath 
bronchial veins. However, mast cell degranulation was not 
prominent in the infiltrate. 
Hamster-+rat transplantation. K76 in doses of 200 mg/kg 
beginning 30 min before revascularization and every 12 hr 
thereafter increased median heart survival from 3 to 4 days 
(Table 2, group 2). The etfect was similar to monotherapy 
with TAC (group 3) or CP (group 4), As reported previously 
(13), combining TAC with subtherapeutic doses of CP in-
creased survival to 5 days (group 5, Table 2), The effect of 
additional K76 was assessed by comparison with group 5. 
Significant prolongation of the survival beyond that ob-
:q 
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TABLE 2. Heterotopic heart and recipient survival after hamster -+ rat xenotranspiantation with K76, tacrolimus, and cyclophosphamide 
Treatment" (duration) 
Median Mortality P Survival Group Induction TACb n (days) (days) (%) (vs. group 5) K76 (mg/kglday) (mg/kg/day) CP (mg/kglday) 
1 6 3, 3, 3, 3, 3, 3 3.0 0 <0.005 
2 200x2 (d 0 to 6) 6 4, 4, 4, 4, 5, 5 4.0 0 0.02 
3 2.0 (d 0 to 13) 6 4, 4, 4, 4, 5, 5 4.0 0 0.02 
4 5 (d-1 to 13) 3 4,4,5 4.0 0 0.06 
5 2.0 (d 0 to 13) 5 (d-1 to 13) 9 5, 5, 5, 5, 5, 5, 5, 6, 6 5.0 0 
6 200x2 (d 0 to 6) 2.0 (d 0 to 13) 5 (d-1 to 13) 6 6, 24c, 26c, 27c , 32", 41c 26.5 83 <0.005 
7 200X2 (d 0 to 6) 2.0 (d 0 to 5) 5 (d-1 to 7) 7 19,28,60, 61c, 68, 89", 61.0 28 <0.001 
>100 
8 200X2 (d 3 to 8) 2.0 (d 0 to 13) 5 (d-1 to 13) 6 18c, 2oe, 2oe, 23c, 3oe, 21.5 100 <0.005 
32" 
9 200X2 (d 3 to 8) 2.0 (d 0 to 5) 5 (d-1 to 7) 8 9", 20, 27, 34, 46c, 54, 40.0 37 <0.001 
61c , >100 
10 200x2 (d 3 to 6) 2.0 (d 0 to 13) 5 (d-1 to 13) 4 27", 30, 30, 31C 30.0 50 <0.01 
11 200X2 (d 0 to 4) 2.0 (d 0 to 13) 5 (d-1 to 13) 5 7,7,7,7,31 7.0 0 <0.005 
12 100x2 (d 0 to 6) 2.0 (d 0 to 13) 5 (d-1 to 13) 4 5,5,6,9 5.5 0 0.35 
13 200X2 (d 0 to 6) 2.0 (d 0 to 13) 4 4,4,5,5 4.5 0 0.09 
14 200X2 (d 0 to 6) 5 (d-1 to 7) 3 7, 7, 7 7.0 0 0.01 
15 200x2 (d 0 to 6) 2.0 (d 0 to 13) 2.5 (d-1 to 13) 6 4,5,5,5,6,26 5.0 0 0.94 
16 200X2 (d 0 to 6) 2.0 (d 0 to 5) 10 (d-1 to 7) 5 lOoe, >100X4 >100 20 <0.005 
a K76 (200 mgJkg) was injected intravenously 30 min before revascularization and continued every 12 hr for days indicated. Cyclophos-
phamide was given only on days indicated. 
b Tacrolimus was continued at daily doses of 1.0 mgJkg (day 6 or 14 to 30) and 0.5 mgJkg (day 31 to 100, every other day). 
C Animal died with beating heart graft. 
tained in group 5 was observed with the addition to TAC/CP 
of a 6-day course of 200 mg of K76 every 12 hr beginning on . 
day 0 (groups 6 and 7) or postoperative day 3 (groups 8 and 
9) and by giving a 4-day K76 course of the same daily doses 
beginning on postoperative day 3 (group 10). The effect of a 
short course ofK76 was largely lost when this was stopped at 
day 4 (group 11), and the effect of a full-duration course was 
lost when this was given at half doses daily (group 12). The 
best median survival time of 61 days (group 7, Table 2) was 
with a 6-day full-dose course of K76, a reduced dose of TAC 
during induction, and an abbreviated course ofCP. The high-
est mortality was associated with the most effective regimens 
for the prevention of rejection; 11 of the 12 rats in groups 6 
and 8 died with beating grafts after 18-41 days (mean, 27 
days), with infection as the usual postmortem diagnosis. 
Although a lower mortality (0-50%) was achieved in the 
experiments of groups 7, 9, 10, and 12 by reducing the cu-
mulative exposure to TAC (groups 7 and 9), CP (groups 7 and 
9), or K76 (groups 10 and 12), the tradeoff was rejection 
within 7-68 days of 14 of the 16 xenografts borne by animals 
who survived to the end of the experiment. 
The dependence of a K76 effect upon the baseline TACICP 
treatment was demonstrated in further experiments. Omis-
sion of either CP (group 13. Table 2) or TAC (group 14) 
eliminated most or all, respectively, of the K76 efficacy. Sim-
ilarly, reducing CP dosage by half in combination with full 
TAC plus K76 dosing reduced heart graft survival time al-
most to that of K76 monotherapy (group 15). In contrast, 
doubling the CP doses (to 10 mgikg per day) allowed consis-
tent animal and graft survival time> 100 days (group 16, 
Table 2)' These results in group 16 were the same as reported 
before the same TAC/CP regimen without K76 was used (131. 
Nonsurvival Studies 
Normal Lewis rats. One hour after an intravenous bolus 
injection of 200 mgikg, K76 plasma levels were 650 iLg/ml. 
Levels decreased rapidly during the next 4 hr, but trace 
concentrations remained at 12.5 hr (Fig. 1A). During the first 
3.5 hr when plasma K76 levels were maintained> 160 iLg/ml, 
C3level, ACH5o, and CHso were suppressed to less than 44%, 
18%, and 76%, respectively. of initial values (Fig. lB). Al-
though CH50 returned to normal by 6 hr, ACH50 and C3 
activity remained depressed to 60% of control at 12 hr. PT 
and APTT were nearly doubled 2 hr after injection, but 
fibrinogen levels were not significantly changed (Fig. lC)' 
After guinea pig-+rat transplantation. Animals pretreated 
for 10 days with TAC and CP (as in group 8, Table 1) were 
given 200 mglkg K76 30 min before and 9.5 and 22.5 hr after 
heart revascularization. The average K76 plasma concentra-
tion was 890 iLg/ml when the xenograft blood supply was 
restored and was maintained between 100 and 300 iLg/ml 
throughout the next day (Fig. 2A), during which time CHf;O. 
ACH5o• and C3 activities were suppressed to <50% of pre-
transplant values (Fig. 2B)' 
However, histopathological examination of the still-func-
tioning grafts 6 hr after transplantation showed evidence of 
focal hemorrhagic myocardial necrosis and varying degrees 
of periarterial hemorrhage (Fig. 3)' These changes were min-
imal for the first 6 hr but slowly increased with time. Heart 
grafts that were still beating 20 hr after transplantation had 
massive hemorrhagic necrosis with coronary thrombosis 
(Fig. 31. 
After hamster-+rat transplantation. Animals pretreated 
with CP for 1 day and started on T AC perioperatively were 
given 200 mg/kg K76 30 min before xenograft revasculariza-
i 
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FIGURE 1. Effect of bolus K76 injection (200 mg/kg) in normal Lewis 
rats (n=21. The values in panels Band C are expressed as percent-
ages of initial value in normal Lewis rats. (A) Plasma K·76 level; (B) 
complement activity; (C) PT, APTT, and fibrinogen levels. 
tion and every 12 hr thereafter (as in group 7, Table 2). K76 
plasma levels were maintained between 50 and 400 /l-g/ml. 
For 5 days after transplantation. antihamster lymphocyto-
toxic antibody increased from the initial level of 25 to 28 , an 
elevation similar to that in untreated animals (data not 
shown I and in animals of group 5 (Table 2) treated with only 
CP and TAC (Fig. 4Al. The titers in the K76-treated animals 
whose heart grafts still beat receded subsequently and pla-
teaued at a higher level than before operation throughout the 
rest of the month (Fig. 4A). CH~o, ACH~(h and C3 levels were 
markedly suppressed during the 6 days of K76 treatment 
(I1QIml) 
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FIGURE 2. Effect of K76 in recipients of guinea pig hearts treated 
with K76, TAC, and CP as in group 8 (Table 1, n=1-3). K76 (200 
mg/kg) was given 30 min before revascularization and repeated 
every 9-12 hr after grafting. TAC (1.0 mg/kg per day) and CP (7.5 
mg/kg per day) were given for 10 days before operation. The values 
in panel B are expressed as percentages of normal Lewis rats. (A) 
Plasma K76 level after transplantation; (B) CH5o• ACHso• and C3 
levels. 
(Fig. 4B). The hearts had histopathologic findings of rejection 
similar to those reported previously (14), 
DISCUSSION 
The therapeutic implication of inhibiting or depleting com-
plement has been a recurring theme of transplantation re-
search since the HAR syndromes were recognized in allograft 
recipients who had preformed antigraft antibodies (15-17), 
the same events were described in discordant xenotransplant 
models (18), and Gewurz et a1. (19) demonstrated that the 
HAR of organ allografts and xenografts was a complement 
activation syndrome. Sporadic clinical reports in which anti-
graft antibodies could not be detected (20) showed that the 
complement activation of HAR could occur by the alternative 
as opposed to the classical antibody-initiated pathway. The 
analogy to the Shwartzman reaction (21, 22) and recognition 
that vulnerability of the graft microvasculature is the critical 
pathogenetic feature were also well-known features of HAR 
more than 25 years ago (22). 
---~------
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FIGURE 3. Guinea pig heart grafts in recipients treated with K76, 
TAC, and CP as group 8 (Table 1). (A) At 1.5 hr after revasculariza-
tion, slight endothelial degeneration and neutrophil aggregation 
with perivascular edema were seen without any remarkable changes 
in cardiac parenchyma. (B) Three hours after revascularization, sim-
ilar changes were seen 1.5 hr after transplantation, with evident 
neutrophil infiltration in the perivascular area. Parenchyma re-
mained relatively normal. (C) By 6 hr after revascularization, mod-
erate endothelial edema and mild vascular smooth muscle degener-
ation had occurred. A subpopulation of cardiac muscle showed mild 
to moderate degeneration with slight congestion. (m At 20 hr after 
transplantation, arteries and veins had severe vascular damage, 
with fibrin thrombus and congestion. Marked degeneration and ne-
crosis with congestion and hemorrhage were seen in parenchyma 
without inflammatory cell infiltration (hematoxylin and eosin, 
x 100). 
Complement inhibition to control HAR was first attempted 
with crude cobra venom (19) only slightly less successfully 
than with the more controllable and less toxic cobra venom 
fraction (CVF), which causes profound depletion ofC3, factor 
B, and terminal components of the membrane attack complex 
(23,24). Two other relatively nontoxic drugs allow interdic-
tion of the complement cascade at levels that block the alter-
native as well as the classical pathway: soluble complement 
receptor type 1 (25-27), which acts as C3 and C5 convertase, 
and the sesquiterpene compound K76 of the present study. 
Although these three "modern" agents dramatically extend 
whole organ survival in so-called discordant xenotransplant 
models, HAR promptly supervenes when treatment is 
stopped or develops slowly even when it is continued. 
Evidence that K76 inhibits the C5 step of complement 
activation was obtained by exposing sensitized sheep red 
blood cells incubated with K76 to guinea pig complement at 
various stages of the complement activation cascade (1). 
However, a 15-25% step inhibition of C2 and C3 also occurs 
(2), but not enough to explain the lack of tissue C3 deposition 
in K76-treated rat recipients of hamster kidneys (28) and in 
a rabbit model of ulcerative colitis (5), or to explain the 
profound C3 depression reported herein. K76 may cause in-
appropriate C3-target cell binding, which could be the ulti-
mate explanation for the failure of C5 activation (W. 
Miyazaki. unpublished data). Whatever the principal site of 
action. it is far enough along the complement cascade to 
suppress both the classical and alternative pathways. an 
important notation because both are thought to participate in 
the hyperacute xenograft rejection characteristic of the 
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FIGURE 4. Effect ofK76 in recipients of hamster hearts treated with 
K76. TAC, and CP as group 7 (Table 2. n=31. K76 (200 mglkg) was 
injected intravenously 30 min before revascularization and contin-
ued every 12 hr for 6 days (days 0-6). TAC was injected intramus-
cularly at 2.0 mglkg per day on days 0-5, 1.0 mglkg per day on days 
6-30. and 0.5 mglkg per day every other day thereafter. CP was 
given orally at a daily dose of 5.0 mglkg for 9 days (days -1 to 7). The 
values are expressed as percentages of normal Lewis rats. (A) Anti-
hamster lymphocytotoxic antibody titer using CDCC assay (0, anti-
body levels in normal LEW rats); (8) CHoo. ACH5o• and C3 levels. 
guinea pig-rat model (29. 30). Failure of anti-/-L antibodies to 
have a strong therapeutic effect in this difficult model (30) 
has been construed as evidence of the importance of alterna-
tive pathway activation. 
The ability of K76 to delay guinea pig heart HAR by the rat 
was comparable to that of CVF (31. 32) and soluble comple-
ment receptor type 1 (25. 26). However. the price was a high 
mortality. roughly proportional to the duration of heart xe-
nograft survival. In contrast to this "toxicity" in the guinea 
pig xenograft rat recipients. K76 was well tolerated in unal-
tered rats and caused no mortality when used twice daily for 
6 days as mono therapy for rat recipients of hamster hearts. 
The greater than 50% mortality of rats bearing guinea pig 
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xenografts for long periods was usually due to respiratory 
arrest, which suggests that the continued perfusion of the 
xenografted heart was the lethal factor, possibly because of 
accumulation of anaphylatoxins. 
Anaphylatoxins are associated with degranulation of mast 
cells and basophils, and release of mediators that induce 
neutrophil aggregation, smooth muscle contraction, and in-
creased vascular permeability. The neutrophil infiltration 
beneath bronchial veins and the evidence of smooth muscle 
contractions in K76-treated recipients of guinea pig hearts 
were consistent with this pathogenesis of respiratory failure. 
Respiratory arrest has also been seen after guinea pig-rat 
heart transplantation when the xenograft survival was pro-
longed with the normally nontoxic anti-inflammatory drug 
lisofylline (unpublished observations). 
The high death rate of rat recipients whose guinea pig 
hearts were still beating made it impossible to establish with 
certainty whether adjuvant therapy with TAC and/or CP 
augmented the dramatic effect of K76 on xenograft survival. 
With the easier hamster heart-rat model, this was feasible, 
but only under restrictive experimental conditions. When 
K76 was given every 12 hr as the sole treatment for as long 
as the transplanted heart beat, median hamster xenograft 
survival time was increased from 3 to 4 days (P=0.02), the 
same prolongation as with monotherapy using daily thera-
peutic doses of TAC or suboptimal doses of CPo When used 
together, the three agents were synergistic, with loss of ef-
fectiveness if anyone of the three agents was omitted, if the 
already suboptimal CP dose was reduced further, or if K76 
administration was stopped short of the posttransplant days 
5 and 6, during which time the development of xenogeneic 
antibodies characteristic of this model reaches a peak. The 
median survival time in the best combined treatment group 
was 61 days, only slightly better than the 49 days reported by 
Van den Bogaerde et al. (33) using cyclosporine in combina-
tion with CVF. Because the half-life of an intravenous bolus 
of K76 is less than 6 hr compared with the 30 hr of CVF (24), 
maintenance of stable blood levels was undoubtedly less 
even. 
However, the results with the best K76-containing triple-
agent regimen were distinctly inferior to what has been re-
ported with optimal dosing of TAC or cyclosporine combined 
with CP (13, 34) or other antimetabolite drugs (13) with 
which 100% hamster heart survival for 100 days in rat re-
cipients can be routinely obtained. The high mortality of the 
K76-containing regimens stemmed largely from infection, 
including the frequent presence of microabscesses in the 
liver. However, the infections were not attributable per se to 
the K76, but rather to inadequate control of rejection, which 
was almost universal. The role of inadequate control of re-
jection in causing infection was demonstrated by negative 
example in animals of group 16 (Table 2) given optimal 
TAC/CP treatment to which K76 was added. All of these rats 
survived with beating hearts for 100 days. as described pre-
viously using the same doses of TAC/CP alone. 
In conclusion. K76 is a powerful inhibitor of complement 
activation and appears to interrupt both the classical and 
alternative activation cascades. It dramatically delays the 
hyperacute rejection of discordant xenografts and can also 
augment minimally etfective TAC/CP regimens in concor-
dant models. However. efficient complement inhibition ap-
peared to be a relatively fruitless strategy tor both the dis-
cordant and concordant xenotransplantation models used in 
our experiments. After guinea pig-rat transplantation, the 
prolongation of xenograft survival correlated with a high 
mortality that was associated more with the continued pres-
ence of the xenograft in the circulation than with use of the 
anticomplement agent. With hamster-rat transplantation, 
the results when K76 was combined with TAC and low-dose 
CP were no better than with appropriate doses of TAC and 
CP only. 
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